1-20 of 828 results for subject:Clostridium
Librarians' tools
- Search time
- 0.341 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:Clostridium
- We searched for
- subject_t:Clostridium OR subject_t:"C. difficile" OR subject_t:Clostridia OR subject_t:"Clostridium botulinum" OR subject_t:"Clostridium difficile" OR subject_t:"Clostridium perfringens" OR subject_ses:9216
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government what information they hold on the availability of Vancomycin for the treatment of Clostridium difficile in pharmacies across the country.
To ask Her Majesty's Government what information they hold on the availability of Vancomycin for the treatment of Clostridium difficile in pharmacies across the country.
The Department fully understands that maintaining access to vancomycin for the treatment of Clostridium difficile is vitally important to many people in this country.
We are aware that two manufacturers of vancomycin capsules are currently experiencing supply issues. However, alternative manufacturers have supplies available and there are sufficient supplies available to continue to meet normal United Kingdom demand.
We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.
To ask the Secretary of State for Health and Social Care, what estimate he has made of (a) the per patient cost to the NHS of treating C-difficile infection (b) the cost the NHS of treating bed-bound patients in hospitals as a result of that infection in the latest period...
To ask the Secretary of State for Health and Social Care, what estimate he has made of (a) the per patient cost to the NHS of treating C-difficile infection (b) the cost the NHS of treating bed-bound patients in hospitals as a result of that infection in the latest period...
Using data from United Kingdom hospitals, in 2017, Public Health England (PHE) estimated the cost of the first episode of Clostridium difficile (C. difficile) infection to be approximately £6000. This can be viewed at the following link:
https://academic.oup.com/jac/article/72/9/2647/3867671
No estimate has been made of the cost to the National Health Service of treating bed-bound patients in hospital with C. difficile infection.
Severity definitions are not applied or recorded systematically for C. difficile. Therefore, it is not possible to estimate the cost to the NHS.
National statistics on C. difficile infection do not include the number or rate of recurrent cases in the United Kingdom therefore it is not possible to estimate the cost of treating patients with recurrent C. difficile to the NHS.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with (a) severe or life-threatening and (b) acute or mild C-difficile infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with (a) severe or life-threatening and (b) acute or mild C-difficile infection.
Using data from United Kingdom hospitals, in 2017, Public Health England (PHE) estimated the cost of the first episode of Clostridium difficile (C. difficile) infection to be approximately £6000. This can be viewed at the following link:
https://academic.oup.com/jac/article/72/9/2647/3867671
No estimate has been made of the cost to the National Health Service of treating bed-bound patients in hospital with C. difficile infection.
Severity definitions are not applied or recorded systematically for C. difficile. Therefore, it is not possible to estimate the cost to the NHS.
National statistics on C. difficile infection do not include the number or rate of recurrent cases in the United Kingdom therefore it is not possible to estimate the cost of treating patients with recurrent C. difficile to the NHS.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection in each of the last three years.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection in each of the last three years.
Using data from United Kingdom hospitals, in 2017, Public Health England (PHE) estimated the cost of the first episode of Clostridium difficile (C. difficile) infection to be approximately £6000. This can be viewed at the following link:
https://academic.oup.com/jac/article/72/9/2647/3867671
No estimate has been made of the cost to the National Health Service of treating bed-bound patients in hospital with C. difficile infection.
Severity definitions are not applied or recorded systematically for C. difficile. Therefore, it is not possible to estimate the cost to the NHS.
National statistics on C. difficile infection do not include the number or rate of recurrent cases in the United Kingdom therefore it is not possible to estimate the cost of treating patients with recurrent C. difficile to the NHS.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of incidences of an outbreak of c-difficile Infection in NHS hospitals after a single case of that infection was diagnosed.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of incidences of an outbreak of c-difficile Infection in NHS hospitals after a single case of that infection was diagnosed.
Public Health England (PHE) does not run surveillance of Clostridium difficile infection (CDI) outbreaks. Data are captured at the case level and this is published as national statistics on the incidence of the disease.
Cases are categorised based on their timing of detection, in relation to admission to hospital and the patient’s prior exposure to hospital. The national statistics do not group cases into outbreaks. If there is clinical suspicion of an outbreak, then local Infection Prevention and Control teams will investigate further but this is outside the scope of national mandatory surveillance.
To ask the Secretary of State for Health and Social Care, what proportion of community-acquired c-difficile infections require hospitalisation.
To ask the Secretary of State for Health and Social Care, what proportion of community-acquired c-difficile infections require hospitalisation.
Public Health England (PHE) does not collect data on community-acquired Clostridium difficile infections (CDI). However, PHE collects data on community-onset CDI. Community-onset CDI are those cases occurring without or within two days of a hospital admission.
In approximately half of the community-onset CDI cases (50.1% or 3,706/399 cases), the patient was either admitted to hospital at the time of the first positive sample or admitted shortly afterwards.
It should be noted that this information is in part reliant on completion of an optional data field and therefore ascertainment may not be optimal. PHE does not collect information on the reasons of the patient being admitted to the hospital. Therefore, in some cases the admission to hospital may have been for other reasons than the CDI.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection.
National statistics on Clostridioides difficile (C. difficile) infection do not include the number or rate of recurrent cases in the United Kingdom therefore it is not possible to estimate the cost of treating patients with recurrent C. difficile to the National Health Service.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of incidences of an outbreak of C-Difficile Infection in NHS hospitals after a single case of that infection was diagnosed.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of incidences of an outbreak of C-Difficile Infection in NHS hospitals after a single case of that infection was diagnosed.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with recurrent C-difficile infection.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, what proportion of community-acquired c-difficile infections require hospitalisation.
To ask the Secretary of State for Health and Social Care, what proportion of community-acquired c-difficile infections require hospitalisation.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost per patient of treating patients who contract C-difficile infection; and what estimate he has made of the cost of additional bed-bound patients in hospitals as a result of that infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost per patient of treating patients who contract C-difficile infection; and what estimate he has made of the cost of additional bed-bound patients in hospitals as a result of that infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with (a) severe or life-threatening and (b) acute or mild C-difficile infection.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of treating patients with (a) severe or life-threatening and (b) acute or mild C-difficile infection.
To ask the Secretary of State for Health and Social Care, how many trust-apportioned Clostridium Difficile cases were reported in each year since 2010-11.
To ask the Secretary of State for Health and Social Care, how many trust-apportioned Clostridium Difficile cases were reported in each year since 2010-11.
Public Health England publishes the annual counts and rates of Clostridium difficile (C. difficile) infections by acute trust and clinical commissioning group in patients aged two years and over at the following link:
https://www.gov.uk/government/statistics/clostridium-difficile-infection-annual-data
A copy of the table showing the financial year counts and rates of C. difficile infection for patients aged two years and over by acute trust (trust apportioned cases only) is attached
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...